Literature DB >> 15305867

Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation.

Giuseppe Sancesario1, Mauro Giorgi, Vincenza D'Angelo, Anna Modica, Alessandro Martorana, Maria Morello, C Peter Bengtson, Giorgio Bernardi.   

Abstract

Dopamine and NO are physiological stimulators of synthesis of cAMP and cGMP, respectively, and NO synthase-containing interneurons in the striatum are physiologically activated by dopamine-containing neurons in the substantia nigra. This study investigated whether lesioning dopamine neurons has multiple consequences in the striatum consistent with the reported sensitization of cAMP synthesis, including alteration of the NO-cGMP pathway and phosphodiesterase-dependent metabolism of cyclic nucleotides. The substantia nigra of adult Sprague-Dawley rats was unilaterally lesioned with 6-hydroxydopamine. Two months later, we determined expression of NO synthase and evaluated cGMP and cAMP levels of intact and deafferented striatum. Moreover, we evaluated cAMP- and cGMP-phosphodiesterase activities in basal conditions and after Ca2+-calmodulin stimulation and determined the expression of the phosphodiesterase-1B isoform and the levels of phosphodiesterase-1B mRNA. Using immunocytochemistry we characterized the distribution of NO synthase and phosphodiesterase-1B within striatal neurons. In the dopamine-deafferented striatum, NO synthase levels were decreased by 42% while NO synthase-immunopositive intrastriatal fibres but not NO synthase neuronal bodies were reduced in number. In the deafferented striatum basal cGMP levels were reduced, and cAMP levels were increased, but cGMP-phosphodiesterase and cAMP-phosphodiesterase activities were both increased in basal and Ca2+-calmodulin-stimulated conditions. Accordingly, phosphodiesterase-1B expression and phosphodiesterase-1B mRNA were upregulated while a large population of medium-sized striatal neurons showed increased phosphodiesterase-1B immunoreactivity. Dopamine deafferentation led to a complex down-regulation of the NO-cGMP pathway in the striatum and to an up-regulation of phosphodiesterase-1B-dependent cyclic nucleotide metabolism, showing new aspects of neuronal plasticity in experimental hemiparkinsonism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305867     DOI: 10.1111/j.1460-9568.2004.03566.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  19 in total

Review 1.  Dopaminergic modulation of striatal function and Parkinson's disease.

Authors:  Shenyu Zhai; Weixing Shen; Steven M Graves; D James Surmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-04-01       Impact factor: 3.575

Review 2.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 3.  Striatal synapses, circuits, and Parkinson's disease.

Authors:  Shenyu Zhai; Asami Tanimura; Steven M Graves; Weixing Shen; D James Surmeier
Journal:  Curr Opin Neurobiol       Date:  2017-08-24       Impact factor: 6.627

4.  Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Authors:  Fernando E Padovan-Neto; Stephen Sammut; Shreaya Chakroborty; Alexander M Dec; Sarah Threlfell; Peter W Campbell; Vishnu Mudrakola; John F Harms; Christopher J Schmidt; Anthony R West
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

5.  Inhibition of dopamine signaling suppresses cGMP accumulation in rd1 retinal organ cultures.

Authors:  Ju Zhang; Angela M Richmond; Judith M Ogilvie
Journal:  Neuroreport       Date:  2014-05-28       Impact factor: 1.837

Review 6.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

7.  Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission.

Authors:  Sara Arcangeli; Alessandro Tozzi; Michela Tantucci; Cristiano Spaccatini; Antonio de Iure; Cinzia Costa; Massimiliano Di Filippo; Barbara Picconi; Carmen Giampà; Francesca Romana Fusco; Salvatore Amoroso; Paolo Calabresi
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-14       Impact factor: 6.200

8.  The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway.

Authors:  Salvatore Galati; Paolo Stanzione; Vincenza D'Angelo; Ernesto Fedele; Francesco Marzetti; Giuseppe Sancesario; Teresa Procopio; Alessandro Stefani
Journal:  J Physiol       Date:  2009-07-21       Impact factor: 5.182

Review 9.  New synaptic and molecular targets for neuroprotection in Parkinson's disease.

Authors:  Paolo Calabresi; Massimiliano Di Filippo; Antongiulio Gallina; Yingfei Wang; Jeannette N Stankowski; Barbara Picconi; Valina L Dawson; Ted M Dawson
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

10.  Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity.

Authors:  Kristina E Hoque; Raksha P Indorkar; Stephen Sammut; Anthony R West
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.